SCHEMBL2945000

SCHEMBL2945000

FC(F)(F)Oc1cccc(-c2cnc3ccc(NCCc4ccccn4)nn23)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 18/20 0.73
MKNK1 Q9BUB5 1/20 0.70
KCNH2 Q12809 2/20 0.60
GAK O14976 1/20 0.60
STK10 O94804 1/20 0.60
YES1 P07947 1/20 0.60
RET P07949 1/20 0.60
PDGFRB P09619 1/20 0.60
CSNK2A2 P19784 1/20 0.60
FLT3 P36888 1/20 0.60
ACVR1 Q04771 1/20 0.60
PKN1 Q16512 1/20 0.60
PIM3 Q86V86 1/20 0.60
HASPIN Q8TF76 1/20 0.60
SIK2 Q9H0K1 1/20 0.60
SLK Q9H2G2 1/20 0.60
BMP2K Q9NSY1 1/20 0.60
PIM2 Q9P1W9 1/20 0.60
PRKAG2 Q9UGJ0 1/20 0.60
RPS6KA6 Q9UK32 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2948030 0.91 PIM1 (0.72) PIM1KCNH2GAKSTK10YES1
SCHEMBL13234330 0.89 PIM1 (0.73) PIM1KCNH2GAKSTK10YES1
SCHEMBL13234304 0.88 MKNK1 (0.74) PIM1MKNK1
SCHEMBL13234318 0.88 PIM1 (0.74) PIM1KCNH2GAKSTK10YES1
SCHEMBL13234308 0.88 PIM1 (0.74) PIM1KCNH2GAKSTK10YES1
SCHEMBL2951158 0.86 MKNK1 (0.74) PIM1MKNK1KCNH2PIM3PIM2
SCHEMBL13234315 0.85 PIM1 (0.73) PIM1KCNH2GAKSTK10YES1
SCHEMBL13234343 0.85 PIM1 (0.73) PIM1KCNH2GAKSTK10YES1
SCHEMBL2943854 0.85 MKNK1 (0.78) PIM1MKNK1
SCHEMBL2948807 0.85 PIM1 (1.00) PIM1KCNH2GAKSTK10YES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 PIM1 365/4885MKNK1 144/4885KCNH2 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.